E-cigarette vapor contains more carcinogenic formaldehyde than regular cigarettes
the ONA take:
E-cigarette vapor may contain cancer-causing formaldehyde at a level 15 times higher than normal cigarettes, according to a new study published in the New England Journal of Medicine.
“We’ve found that there is a hidden form of formaldehyde in e-cigarette vapor that has not typically been measured,” said James Pankow, PhD, co-author of the study along with fellow researchers at Portland State University in Oregon. “People shouldn’t assume these e-cigarettes are completely safe.”
While once believed to be a less harmful alternative to the formaldehyde and toxic chemicals found in the smoke of normal cigarettes, newer e-cigarettes operate at high temperatures that dramatically boost the creation of formaldehyde-containing compounds.
The researchers found that, at high voltage, formaldehyde-releasing agents in e-cigarettes increased a person’s lifetime risk of cancer by five-to-15 times greater than the risk of long-term smoking with regular cigarettes. However, the compounds were not found when they were operated at a lower voltage.
The American Vaping Association, an advocacy group for e-cigarette makers, criticized the study, stating that users wouldn’t normally operate devices at such a high voltage.
E-cigarettes remain unregulated, and representatives from the American Cancer Society stated that the findings from the study stress the importance of FDA oversight.
E-cigarette vapor may contain cancer-causing formaldehyde at a level 15 times higher than normal cigarettes.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Self-Predictions for Well-Being Influence Satisfaction After Mastectomy, Breast Reconstruction
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Gabapentin Improves Postoperative Opioid Cessation, But Not Pain Resolution
- Early Integration of Palliative Care Improves Quality of Life in Advanced Cancer
- Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Cachexia Not Improved With Celecoxib Plus Megestrol vs Megestrol Alone
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Efficacy and Safety of COX-2 Inhibitors for Advanced Non-small-cell Lung Cancer With Chemotherapy: A Meta-analysis
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|